Tumor Microenvironment Reprogramming Improves Nanomedicine-Based Chemo-Immunotherapy in Sarcomas

Scientists tested the mechanotherapeutic ketotifen combined with either pegylated liposomal doxorubicin or pegylated liposomal coencapsulated alendronate–doxorubicin plus anti–programmed cell death protein 1 antibody in mouse models of fibrosarcoma and osteosarcoma.